Navigation Links
ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
Date:6/27/2011

MOUNTAIN VIEW, Calif., June 27, 2011 /PRNewswire/ -- ChemoCentryx, Inc. today announced that the Company's novel CCR2 antagonist significantly improves kidney function and hyperglycemia in experimental models.  These data implicate CCR2-driven processes in the pathology of type 2 diabetes and associated complications such as diabetic nephropathy.  Results were highlighted in a poster presentation entitled "CCR2 Antagonism Improves Renal Function and Hyperglycemia in Preclinical Models of Type 2 Diabetes" at the 71st Scientific Session of the American Diabetes Association held in San Diego.  CCX140, the Company's lead novel, orally available CCR2 antagonist, successfully met its primary endpoint of safety and tolerability in a Phase II clinical trial in type 2 diabetes, while demonstrating clinical activity on glycemic indices following only 28 days of treatment.  CCX140 is currently poised to enter Phase II clinical development for the treatment of diabetic nephropathy.

"In the United States there are more than 31 million patients living with chronic kidney disease, 37% as a result of having diabetes," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "Complicating matters further is the fact that the current standard of care does not stop or reverse progression and with the increasing number of patients who progress to end-stage renal disease each year -- there is a clear demand for better treatment options.  We believe these data demonstrate compelling rationale to move forward CCX140, our most advanced CCR2 antagonist, in a Phase II clinical trial for the treatment of diabetic nephropathy."

CCR2 inhibition was studied in two models of type 2 diabetes:  diet-induced obese mice and db/db mice. Treatment with the CCR2 antagonist significantly improved multiple metabolic/renal parameters in obese, diabetic mice, including hyperglycemia, insulin sensitivity, serum adiponec
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
2. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
4. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
5. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
6. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
7. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
8. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
9. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
10. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
11. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...  The investigational S- equol nutritional supplement may ... such as hot flashes, according to a new peer-reviewed ... .[i] "Current data suggest that women may ... symptoms and possibly additional benefits, such as skin health. ... physicians and health care professionals may consider the use ...
(Date:3/30/2015)... MINNEAPOLIS and ORANGEBURG, N.Y., March 30, 2015 ... Inc. (NASDAQ: VSCI ) shareholders have voted ... held today to approve the previously announced agreement ... "We are pleased with the outcome ... to thank both shareholder groups for approving the ...
(Date:3/30/2015)... March 30, 2015 A team of Chinese ... of a cell-surface receptor that plays a critical role ... discloses many new structural features, which challenge the conventional ... and open a new door for future drug discovery. ... on March 30, the researchers at Shanghai Institute ...
Breaking Medicine Technology:New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 2New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 3New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 5New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 6Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 2Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 4New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 2New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 3New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 4New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 5New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 6
... U.S. Dept. of Defense Continues Study of Copper ... Infections and Improving Indoor Air Quality, NEW ... clinical trails determining the,antimicrobial effectiveness of copper, brass ... Association, announced CDA President Andrew G.,Kireta Sr. ...
... Serious Adverse Reactions, BERKELEY HEIGHTS, N.J., Nov. ... findings from the initial clinical,dosing of G4544, the ... treatment for diseases associated with accelerated bone loss. ... volunteers, has shown good,tolerance with oral bioavailability of ...
Cached Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 2Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 4Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 5
(Date:3/30/2015)... In a recent report published by SF Gate ... effective drug and alcohol treatment for victims suffering from ... to stabilize the addiction treatment programs, and continue to ... alcohol addiction. Harbor Village Detox is extending its addiction ... in New Jersey, in hopes to help circumvent the ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 This ... the forecast period of 2014 to 2019. , ... tumor ablation market is classified into four major ... (including irreversible electroporation, radio-iodine, HIFU and laser ablation) ... global tumor ablation market is classified into three ...
(Date:3/30/2015)... 2015 Tel-Aviv – March 30, 2015 ... announced the closing of $12.5 million in new financing ... Viola Group. The funding will further GlassesUSA's aggressive business ... in the growing global market of online eyewear, both ... by CEO Daniel Rothman, COO Eldad Rothman, and CTO ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 ... promotion on Invisalign. Eligible patients will receive $200 off ... are not particularly interested in wearing a mouthful of ... team, “The use of traditional braces is effective for ... who are already concerned with their oral appearance. The ...
(Date:3/30/2015)... March 30, 2015 Valerie Harper, the ... sitcoms “Rhoda” and “The Mary Tyler Moore Show,” will ... honoring oncology nurses, CURETM magazine announced today. Harper, who ... the Oncology Nursing Society’s 40th Annual Congress on April ... important role oncology nurses play in the lives of ...
Breaking Medicine News(10 mins):Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 2Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 3Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 3
... cancer in men. More than 218,000 men will be diagnosed ... will die . June is Prostate Cancer Awareness Month, and ... the ways men can keep their prostates healthy and be ... by benign prostatic enlargement affect the vast majority of men ...
... from the US. The latest health supplement and raisins import ... did not meet the Chinese safety standards. Earlier Chinese products ... tainted and dangerous. ,The food inspectors at the ... in products shipped by three American companies. The companies are ...
... patient at the University of Michigan Health System hospital got ... set of lungs. The earlier double lung transplant operation ... along with the doctors slated to perform the operations. ... this transplant and give this man another chance for life, ...
... tea possible in just three seconds. ,Researchers have ... of hot water in only three seconds, reports the Daily Mail. ... tap in the standard way, but the innovation comes when they ... pre-set amount of water 220ml, which is sufficient to fill ...
... study, increasing intake of calcium and vitamin D could reduce ... percent. ,The four-year clinical trial included more ... one of three supplement groups: calcium) plus vitamin D, calcium ... developing cancer was 60 percent lower for those who took ...
... a potential new target, Akt2/PKB, a fat metabolism regulatory protein, ... 2 diabetes. ,The study was conducted by ... the University of Pennsylvania School of Medicine. ,When ... signal the liver to stop forming glucose and burn fat. ...
Cached Medicine News:Health News:Tips to Maintain a Healthy Prostate 2Health News:China Turning Tables on the US on Food Import 2Health News:Transplant Patient Gets a New Lease of Life 2Health News:High Intake of Milk may Reduce Cancer Risks by 60 Percent 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: